US20100166821A1 - Anti-Inflammatory, Radioprotective, and Longevity Enhancing Capabilities of Cerium Oxide Nanoparticles - Google Patents

Anti-Inflammatory, Radioprotective, and Longevity Enhancing Capabilities of Cerium Oxide Nanoparticles Download PDF

Info

Publication number
US20100166821A1
US20100166821A1 US11/993,260 US99326006A US2010166821A1 US 20100166821 A1 US20100166821 A1 US 20100166821A1 US 99326006 A US99326006 A US 99326006A US 2010166821 A1 US2010166821 A1 US 2010166821A1
Authority
US
United States
Prior art keywords
cerium oxide
oxide nanoparticles
nanoparticles
disease
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/993,260
Other languages
English (en)
Inventor
Beverly A. Rzigalinski
Ariane M. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EDWARD VIA VIRGINIA COLLEGE OF OSTEOPATHIC MEDICIN
Original Assignee
EDWARD VIA VIRGINIA COLLEGE OF OSTEOPATHIC MEDICIN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EDWARD VIA VIRGINIA COLLEGE OF OSTEOPATHIC MEDICIN filed Critical EDWARD VIA VIRGINIA COLLEGE OF OSTEOPATHIC MEDICIN
Priority to US11/993,260 priority Critical patent/US20100166821A1/en
Publication of US20100166821A1 publication Critical patent/US20100166821A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: VIRGINIA COLLEGE OF OSTEOPATHIC MEDICINE
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/30—Inorganic materials
    • A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Definitions

  • the present invention relates to the field of medicine and treatment of medically relevant diseases, disorders, and complications of injury, inflammation, and aging. More specifically, the invention relates to the use of nanoparticles to treat subjects suffering from various diseases, disorders, and complications due to injury, inflammation, radiation exposure, and aging.
  • cerium oxide nanoparticles prepared by a sol-gel process were utilized to enhance cell longevity.
  • the cerium oxide nanoparticles were proposed to act as free radical scavengers to bring about the observed results.
  • the sol-gel process posed several difficulties. For example, particle size was not well-controlled within the reported 2-10 nm range, making variability between batches high. That is, the process, while satisfactory for producing nanoparticles with free radical scavenging activity, did not reproducibly produce particles of a specific size range. Thus, each batch of particles needed to be tested to confirm the size range and the suitability of the batch for use. In addition, the process resulted in tailing of surfactants used in the process into the final product.
  • the present invention addresses this need in the art by providing a method for the use of cerium oxide nanoparticles in health.
  • the method extends the life of a living cell by exposing the cell to cerium oxide nanoparticles. This exposure reduces or eliminates damage to the cell caused by endogenous and exogenous free radicals.
  • the cerium oxide nanoparticles can be exposed to the cell before, during, or after free radical damage.
  • the present invention provides a method of treating at least one cell with cerium oxide particles.
  • the method generally comprises contacting at least one cell with an amount of cerium oxide nanoparticles that reduces or eliminates damage caused by free radicals.
  • the method can be practiced in vivo as either a therapeutic method of treating a disease or disorder involving free radicals or as a prophylactic method to prevent free radical damage.
  • the method can be practiced in vitro as a research tool to study the effects of free radicals on cells or the effects of combinations of nanoparticles with drugs on cells.
  • the method is practiced with size-limited cerium oxide nanoparticles made by a method other than a sol-gel method.
  • the method can also be practiced ex vivo or in vitro for therapeutic or research purposes.
  • the present invention provides methods of treating individuals suffering from, or suspected of suffering from, a disease or disorder involving free radicals, such as oxygen radicals. It likewise provides methods of treating individuals suffering from, or suspected of suffering from a complication of an injury that results from free radicals, such as oxygen radicals, or results in the production of free radicals, such as oxygen radicals.
  • the methods of the invention comprise administering to an individual (used interchangeably herein with “subject” and “patient”) an amount of cerium oxide nanoparticles sufficient to reduce or eliminate cell, tissue, or organ damage in the individual that is caused by free radicals.
  • the invention encompasses the use of cerium oxide nanoparticles in enhancement of cell and organism longevity, reduction of inflammation and inflammatory disorders, reduction in tissue damage due to inflammatory disorders, and reduction in radiation injury.
  • cerium oxide nanoparticles and compositions comprising cerium oxide nanoparticles are provided.
  • the cerium oxide nanoparticles are size-limited and provided in an amount sufficient to provide one or more doses to a subject in need of, or suspected of being in need of, treatment for a disease or disorder involving free radicals.
  • Compositions may comprise cerium oxide particles of the invention along with one or more other substances, which are typically substances that are biologically tolerable in that they may be exposed to living cells without killing the cells.
  • the other substances are pharmaceutically acceptable substances.
  • Certain aspects of the invention provide for the use of cerium oxide nanoparticles in the treatment of diseases and disorders associated with free radicals, such as oxygen free radicals.
  • the use is in particular for in vivo therapeutic or prophylactic methods of protecting cells from free radical damage.
  • Certain other aspects of the invention provide for the use of cerium oxide nanoparticles in the preparation of compositions for medical use, such as pharmaceutical or therapeutic compositions.
  • a container containing cerium oxide nanoparticles contains a sufficient amount of size-limited cerium oxide nanoparticles made by a method other than a sol-gel method to provide at least one dose of cerium oxide to a subject suffering from, or at risk of suffering from, a disease or disorder involving free radicals, such as oxygen radicals.
  • the container is provided in a package with one or more other containers and/or with one or more articles of manufacture or devices having use in delivery of substances to subjects (e.g., syringes, needles, antiseptic swabs).
  • kits comprising one or more containers are provided.
  • single dose amounts of cerium oxide particles are provided.
  • the single dose is 1 ng to 100 mg per kg weight of subject.
  • FIG. 1 depicts the effects of cerium oxide nanoparticles on the maximum lifespan of mixed neuronal cells in culture.
  • FIG. 2 depicts the effects of cerium oxide nanoparticles on the lifespan of D. melanogaster flies.
  • FIG. 3 depicts the excitation spectra for intracellular cerium oxide nanoparticles during a free radical scavenging event.
  • FIG. 4 depicts a drug distribution graph of tissue cerium content of BALB/c mice after injection with nanoparticles, as assayed by inductively coupled plasma mass spectrometry.
  • FIG. 5 shows the response of brain cell cultures (neuronal death) treated with nanoparticles, as assessed by propidium iodide staining.
  • FIG. 6 shows the response of brain cell cultures (neuronal death) treated with nanoparticles.
  • FIG. 7 demonstrates the response of brain cell cultures treated with nanoparticles in terms of nitric oxide release.
  • FIG. 8 shows the morphological effect of cerium oxide nanoparticles on brain microglia.
  • FIG. 9 shows the effect of pretreatment with cerium oxide nanoparticles on exposure to UV radiation.
  • FIG. 10 demonstrates the effect of pretreatment with cerium oxide nanoparticles on exposure to gamma-irradiation.
  • FIG. 11 shows the effect of pretreatment of a single dose of cerium oxide nanoparticles against free radical mediated injury as compared to a single dose of Vitamin E, n-Acetyl Cysteine, or Melatonin.
  • FIG. 12 shows the effect of pretreatment of a single dose of cerium oxide nanoparticles against free radical mediated injury as compared to multiple doses of Vitamin E, n-Acetyl Cysteine, or Melatonin.
  • FIG. 13 shows the change in female Drosophila life spans when cerium oxide nanoparticles are given to the flies.
  • FIG. 14 demonstrates the change in male Drosophila life spans when cerium oxide nanoparticles are given to the flies.
  • FIG. 15 shows the amount of neuron specific enolase (NSE) in tissue culture medium.
  • FIG. 16 shows the effect of cerium oxide nanoparticles on the longevity of tissue cultures.
  • FIG. 17 demonstrates the effect of paraquat on female Drosophila fed 10 nM cerium oxide nanoparticles.
  • FIG. 18 demonstrates the effect of paraquat on female Drosophila fed 1 uM cerium oxide nanoparticles.
  • FIG. 19 demonstrates the effect of paraquat on male Drosophila fed 10 nM cerium oxide nanoparticles.
  • FIG. 20 demonstrates the effect of paraquat on male Drosophila fed 1 uM cerium oxide nanoparticles.
  • FIG. 21 shows the effect of cerium oxide nanoparticles against traumatic injury as compared to a single dose of other antioxidants when given pre-trauma.
  • FIG. 22 shows the effect of cerium oxide nanoparticles against traumatic injury as compared to a single dose of other antioxidants when given post-trauma.
  • FIG. 23 demonstrates the release of NO by astrocytes in both resting and injured states.
  • FIG. 24 shows the effect of cerium oxide nanoparticles on the release of NO from microglia stimulated with medium conditioned by injured astrocytes for 1 hour.
  • FIG. 25 shows the effect of cerium oxide nanoparticles on the release of NO from microglia stimulated with medium conditioned by injured astrocytes for 3 hours.
  • FIG. 26 shows the effect of cerium oxide nanoparticles on the release of NO from LPS-stimulated microglia.
  • FIG. 27 demonstrates the morphology of microglia after injury or exposure to LPS with and without cerium oxide nanoparticles.
  • cerium oxide nanoparticles available from Nanophase Technologies Corporation (Romeoville, Ill.), Advanced Powder Technology Pty Ltd. (Welshpool, Western Australia), and NanoScale Materials Inc. (Manhattan, Kans.).
  • Nanophase Technology Corporation using specific, patented mechanisms of synthesis, provided consistently reproducibly sized nanoparticles that consistently showed high levels of biological activity. With sizes of 20 nm and below, particles readily entered cells and reduced free-radical mediated damage. Synthesis for these particles has been described in the following patents, the disclosures of the entireties of all of which are incorporated herein by reference: U.S. Pat. No. 6,669,823, U.S.
  • the new source of cerium oxide nanoparticles as compared to those of the inventor's prior invention, provided superior reproducibility of activity from batch to batch, and showed lower toxicity to mammalian cells. It was determined that the cerium oxide nanoparticles used in the present invention were different from the prior nanoparticles in quality and size distribution, factors that significantly contribute to their improved characteristics in treating subjects according to the methods of the invention. In developing the invention, it was determined that, regardless of source, cerium oxide particles having a small size, narrow size distribution, and low agglomeration rate are most advantageous. Also, for delivery, the nanoparticles are advantageously in a non-agglomerated form.
  • cerium oxide nanoparticles are superior to previously developed cerium oxide nanoparticles for treatment of and protection against, damage caused by free radicals.
  • This new and useful improvement allows cerium oxide nanoparticles to be used in extending the life of a cell in vivo as well as in vitro.
  • cerium oxide nanoparticles of a defined size range and distribution and made by a method other than sol-gel synthesis increase the lifespan of cells, such as cells of an organism in vivo.
  • cerium oxide nanoparticles enhance the lifespan of mammalian cells in culture and in vivo, act as potent free radical scavengers, and possess significant anti-inflammatory and radioprotective properties in vivo.
  • cerium oxide nanoparticles While not wishing to be limited to any single method of action, it is thought that cerium oxide nanoparticles have a unique oxide lattice and valence structure that might confer them with the ability to scavenge (detoxify) intracellular free radicals, and might thus convey their anti-inflammatory, radioprotective, and longevity-enhancing properties. Further, the data obtained by the inventors, and provided herein, suggests that the valence and oxygen lattice structure conveys the ability of cerium oxide nanoparticles to regenerate a biologically active matrix after a free radical scavenging event. This allows small, single doses of nanoparticles to remain active within the cell for long periods of time, conveying regenerative biological effects.
  • cerium oxide serves to facilitate oscillation of electrons (or free radicals) from one compound to another.
  • Cerium in the nanoparticles exists in two valence states, +3 and +4.
  • Adequate propagation of B-Z requires a specific ratio of Ce+3 to +4 in the nanoparticles. If the composition changes to have too much +3 cerium, the reaction will not propagate.
  • the present invention provides a method of treating at least one cell with cerium oxide particles.
  • the method generally comprises contacting at least one cell with an amount of cerium oxide nanoparticles that reduces or eliminates damage caused by free radicals, which are unstable, highly reactive molecules such as nitric oxide, superoxide, hydroxyl radicals, peroxynitrite, and other unstable reactive compound formed from the above. They cause aging and various diseases by taking electrons from other molecules in the body, a process that causes cell or oxidative damage.
  • free radicals which are unstable, highly reactive molecules such as nitric oxide, superoxide, hydroxyl radicals, peroxynitrite, and other unstable reactive compound formed from the above. They cause aging and various diseases by taking electrons from other molecules in the body, a process that causes cell or oxidative damage.
  • cell or oxidative damage has the same meaning as oxidative stress.
  • Contacting means any action that results in at least one cerium oxide nanoparticle physically contacting at least one cell. It thus may comprise exposing the cell(s) to cerium oxide nanoparticles in an amount sufficient to result in contact of at least one cerium oxide nanoparticle with at least one cell.
  • the method can be practiced in vivo, in which case contacting means exposing at least one cell in a subject to at least one cerium oxide nanoparticle.
  • contacting thus may comprise exposing at least one cell to at least one cerium oxide particles, such as, for example by administering cerium oxide particles to a subject via any suitable route.
  • It also may comprise exposing cells in vitro or ex vivo by introducing, and preferably mixing, cerium oxide particles and cells in a controlled environment, such as a culture dish or tube.
  • a controlled environment such as a culture dish or tube.
  • some or all of the cerium oxide particles that are not taken up or adsorbed by cells are removed, for example by washing the cells in suitable media, buffer, water, etc.
  • contacting may comprise introducing, exposing, etc. the cerium oxide particles at a site distant to the cells to be contacted, and allowing the bodily functions of the subject, or natural (e.g., diffusion) or man-induced (e.g., swirling) movements of fluids to result in contact of the nanoparticle(s) and cell(s).
  • the cells may also be re-introduced into a subject, preferably the subject from which they were originally obtained. In one embodiment, this includes putting the particles into a gel or other packet that limits diffusion, followed by implanting it into a body area such as a knee joint.
  • the subject, individual, or patient can be any organism to whom the cerium oxide nanoparticles are administered.
  • the subject may be a human or a non-human animal, such as another mammal, including, but not limited to a rodent (e.g., mouse, rat, rabbit), a canine (e.g., a dog), a feline (e.g., a cat), an equine (e.g., a horse), an ovine (e.g., a sheep), an orcine (e.g., a pig), or a bovine (e.g., a cow or steer).
  • the subject can be any other animal such as a bird, reptile, amphibian, or any other companion or agricultural animal.
  • the method can be practiced in vivo as either a therapeutic method of treating a disease or disorder involving free radicals or as a prophylactic method to prevent free radical damage.
  • the method is a method of treating (i.e., a therapeutic method)
  • the amount is an amount that is effective for reducing or eliminating cell death or dysfunction or tissue or organ damage due to free radicals that are being produce, or were produced previously, in the subject.
  • the subject, individual, or patient may be one who is in immediate or apparent need of, or suspected of being in need of, treatment for a disease or disorder associated with free radicals, or it may be one who is in immediate or apparent need of, or suspected of being in need of, treatment for an injury or other trauma resulting from or known to result in production of free radicals.
  • the method is a therapeutic method.
  • a subject has had a stroke, it may be beneficial to treat the subject with cerium oxide nanoparticles to reduce the effects of the stroke.
  • the subject, individual, or patient may be one who is not in or suspected of being in need of treatment of a pre-existing disease, disorder, or injury or trauma.
  • the method is a prophylactic method.
  • Prophylactic methods are useful in situations where the subject is currently engaged in, or soon to be engaged in, one or more activities that might result in an injury or trauma. They are also useful in situations where the patient has a likelihood of developing a disease or disorder associated with cell, tissue, or organ damage due to free radicals.
  • the present methods are useful not only for treating patients with a disease or disorder, but for treating patients who are suspected of having a predisposition to a disease or disorder.
  • cerium oxide nanoparticles For example, if the family of a subject has been shown to be prone to a certain neurodegenerative disease, the subject may be given cerium oxide nanoparticles to avoid or reduce the effects of that disease. Likewise, if a subject suspects he will be exposed to high levels of radiation, such as a worker in the nuclear energy or weapons industries, or a person about to go on a vacation in which he will be exposed to high levels of sunlight and its UV component, may be treated with the cerium oxide nanoparticles of the invention. In another example, military uniforms, including clothes and helmets, can be made containing cerium oxide nanoparticles to scavenge free electrons and gamma irradiation for troops exposed to potential radiation.
  • the amount is an amount that is effective in reducing or blocking cell death or dysfunction or tissue or organ damage due to free radicals that might be produced in the subject in the future.
  • the cerium oxide nanoparticles may be administered to a patient following a head injury to reduce the amount of damage to the brain as a result of the injury.
  • the cerium oxide nanoparticles may be administered to a subject prior to engaging in an activity that has a likelihood of head injury, such as a car race or other high-speed activity.
  • the act of administering cerium oxide nanoparticles can be any act that provides the cerium oxide nanoparticles to a subject such that the particles can function for their intended purpose.
  • administering can be by injection or infusion. It can thus be an intramuscular, intraparatoneal, subcutaneous, or intrathecal injection, or a slow-drip or bolus infusion.
  • Other non-limiting examples of methods of administration include topical administration, such as by way of lotions, salves, or bandages, often on intact skin but also through open wounds, lesions, or sores.
  • Non-limiting examples include administration through mucous membranes, such as by way of intranasal administration through inhalation of dry particles or a mist comprising the particles, oral ingestion, sublingual absorption, by subcutaneous means, and rectal or vaginal delivery.
  • the vehicle of delivery may be in any suitable form, such as the form of an oral solution, gel, tablet, capsule, powder, suppository, infusible, losenge, cream, lotion, salve, inhalant, or injection.
  • the method can comprise repeating the act of contacting (e.g., administering) the cerium oxide nanoparticles.
  • repeating the administration can include one or more administrations in addition to the original administration.
  • the amount to be administered to each subject will vary depending on usual factors taken into consideration for dosing of pharmaceuticals, such as weight, general health, and metabolic activities of the patient.
  • the mode of administration e.g., injection, oral administration
  • a dosing of about 0.01 ng to about 1 g such as about 0.05 ng, 0.1 ng, 0.5 ng, 1 ng, 10 ng, 50 ng, 100 ng, 500 ng, 1 ug, 5 ug, 10 ug, 50 ug, 100 ug, 500 ug, or 1 g per administration or per kg body mass per administration should be effective in providing the desired therapeutic or prophylactic result.
  • injection or infusion amounts will tend to be on the lower end of the range while oral administration amounts will tend to be on the upper end.
  • Current results suggest that the optimal dose for 20 nm cerium oxide nanoparticles is 10 nM to 1 uM for blood and intracellular fluid levels.
  • the action of the particles is highly dependent on other variables and so these amounts will vary depending on the surface area, the species of the subject, the reason for administration etc. Amounts may be higher when the method is practiced in vitro or ex vivo because excess particles may be easily removed at any time by washing, etc.
  • this method shows low toxicity in mammalian cells, fruit flies, and mice, and thus is expected to show low toxicity in other animal cells.
  • This new and useful improvement allows the method of the present invention to be used in subjects with lower toxicity than in previous inventions.
  • This important feature of the present invention means that the cerium oxide nanoparticles can be used in a broad range of applications.
  • the cerium oxide nanoparticles do not contain docusate sodium, which has been shown to produce toxicity in tissue culture.
  • the cerium oxide nanoparticles show very low toxicity, in some instances it might be desirable to provide multiple, low doses of particles to an individual.
  • the method may comprise two or more administrations of less than the total effective amount, where the amount ultimately administered is an effective amount.
  • multiple administrations of an effective dose may be desirable where the second or subsequent administration is performed at a time well separated from the first administration. That is, because the cerium oxide nanoparticles are highly stable, even after being administered, repeated administrations of effective doses are envisioned as occurring at widely spaced intervals, such as months or years apart.
  • different modes of administration may be used. For example, if two doses are administered, one can be an injection whereas the other can be oral. In addition, if three or more doses are administered, two or more may be by the same mode, while the remaining may be from one or more different mode, in any combination, number, and order. Of course, where multiple administrations are used, each administration may be by a different mode. The mode of administration, the number of times it is repeated, and the sequence of modes of administration may be selected by those of skill in the art based on numerous considerations, and such selection is well within the abilities of those of skill in the art.
  • the method can also be practiced in vitro which means that contacting at least one cell with at least one cerium oxide nanoparticle can occur in a petri dish, a test tube, an IV tube, or any other container applicable for contacting.
  • it may be a method for identifying parameters that are useful in in vivo treatment regimens.
  • the method can be practiced to study the effects of combinations of nanoparticles with drugs on cells.
  • the cerium oxide nanoparticles can be combined with other known antioxidants such as vitamin E, n-acetyl cysteine, or melatonin.
  • the cerium oxide nanoparticles could also be combined with disease specific drugs.
  • the in vitro methods can also comprise using the cerium oxide nanoparticles as a research tool to observe the effects of free radicals on cells or observe the cells for changes in protein expression, cell morphology, or any other characteristic of interest.
  • the method is practiced with size-limited cerium oxide nanoparticles made by a method other than a sol-gel method.
  • the nanoparticles useful in the present invention have pre-defined sizes clustered tightly within a range.
  • the particles have a size of about 1 nm or less to about 500 nm.
  • the particles are 11 nm or more.
  • the preferable range of particles that are taken into the cell are from about 11 nm to about 50 nm, such as about 20 nm.
  • the preferable range of particles that are extracellular are from about 11 nm to about 500 nm.
  • the particles are from about 40 nm to about 500 nm. In other embodiments, the particles are from about 11 nm to about 40 nm, such as from about 11 nm to about 20 nm, about 15 nm to about 20 nm, about 11 nm to about 15 nm, or about 30 nm to 40 nm.
  • any specific size range within these general sizes can be provided, the size being selected by the practitioner based on any number of parameters. According to the invention, the term “about” is used to indicate a margin of error for a statistically significant portion of the particles of 10%.
  • particles of a size of 20 nm include those in which a majority of the particles fall within the range of 18 nm to 22 nm.
  • 95% of the cerium oxide nanoparticles have a size of between about 15 nm and about 25 nm. In embodiments, 95% of the cerium oxide nanoparticles are within 5% of 20 nm. In other embodiments, 90% of the cerium oxide nanoparticles have a size of between about 18 nm and about 22 nm.
  • the present invention provides methods of treating individuals suffering from, or suspected of suffering from, a disease or disorder involving free radicals, such as oxygen radicals. It likewise provides methods of treating individuals suffering from, or suspected of suffering from a complication of an injury that results from free radicals, such as oxygen radicals, or results in the production of free radicals, such as oxygen radicals.
  • the methods of the invention comprise administering to an individual (used interchangeably herein with “subject” and “patient”) an amount of cerium oxide nanoparticles sufficient to reduce or eliminate cell, tissue, or organ damage in the individual that is caused by free radicals.
  • the invention encompasses the use of cerium oxide nanoparticles in enhancement of cell and organism longevity, reduction of inflammation and inflammatory disorders, reduction in tissue damage due to inflammatory disorders, and reduction in radiation injury.
  • a method according to the invention can comprise removing at least one cell from an organism, administering cerium oxide nanoparticles to that cell, then returning the cell to its natural environment (e.g., into the body of the patient).
  • the act of administering can be simply exposing the nanoparticles to the cell, for example in a culture dish or a tube.
  • the method of ex vivo administration comprises obtaining blood from a patient, exposing the blood to cerium oxide nanoparticles, and returning the treated blood to the patient.
  • the method can comprise separating cerium oxide nanoparticles from the blood prior to returning the blood to the patient.
  • the cerium oxide nanoparticles allow an increase in longevity of prokaryotic cells. For example, adding the cerium oxide nanoparticles to a large scale E. coli cell culture to allow longer production of overexpressed protein may allow more efficient and cost effective production.
  • Relevant human proteins that could be overexpressed include antibody fragments, single-domain antibodies, and any other protein important in human health, including what are presently known as “biologicals” in the pharmaceutical industry.
  • the cerium oxide nanoparticles allow an increase in longevity of eukaryotic cells.
  • the nanoparticles could be used to increase the longevity of yeast cell cultures that produce human proteins.
  • yeast cultures that produce human proteins significant in human health such as Bacillus anthracis protective antigen, hepatitis vaccines, and malaria antigens could be grown for longer periods of time.
  • Continuous fermentation using immobilized yeast cell bioreactor systems to produce consumable and other products, such as beer could also benefit with increased longevity of the yeast cells after addition of cerium oxide nanoparticles.
  • the same effect of the cerium oxide nanoparticles could be used in plant cell cultures, such as cultures producing human vaccine antigens or other human proteins.
  • mammalian cell cultures that produce recombinant human antibodies and other important proteins for human health could benefit from increased longevity due to the addition of cerium oxide nanoparticles.
  • the present invention is used to affect, either prophylactically or therapeutically, cell longevity in organisms.
  • the methods treat or affect, either prophylactically or therapeutically, diseases or disorders associated with free radicals, or cell death or tissue or organ damage due to free radicals.
  • the methods comprise administering to a subject an amount of cerium oxide nanoparticles sufficient to reduce, eliminate, or block cell, tissue, or organ damage caused by free radicals in the subject.
  • the cerium oxide nanoparticles can be taken up by the cell. In this case, they can act to reduce or eliminate free radicals within the cell.
  • This method can be used for the prevention or treatment of brain disease, spinal cord disease, or other neurological trauma. This method can also be used for the treatment or prevention of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, toxin-mediated damage, or stroke.
  • This method may be used in the treatment or prevention of cardiovascular disease, diabetes, diseases of the retina, asthma, respiratory dysfunctions, and allergic or autoimmune diseases, such as chronic obstructive pulmonary disease and lupus. It is to be understood that the diseases stated above are only examples and are not to be understood as limiting the invention in anyway.
  • the cerium oxide nanoparticles are not taken up in any significant amount by the cells, but go into intravascular or interstitial spaces.
  • the nanoparticles can act to reduce or eliminate free radicals outside the cell. This can result in reduction of inflammation and inflammatory disorders.
  • the cerium oxide nanoparticles can reduce inflammation systemically (throughout a subject's body) or locally (at the site of the inflammatory cells).
  • the nanoparticles can reduce or eliminate inflammation that leads to preeclampsia or inflammation caused by wounding. This can also reduce or eliminate inflammation caused by the insertion of a medical prosthesis into the subject.
  • Nanoparticles may be retained at particular sites, at least substantially retained for periods of time, by inclusion of the nanoparticles into compositions, such as dissolvable or porous matrices and the like.
  • the cerium oxide nanoparticles can also contact the surface of the subject's skin and increase cell and organism longevity on the surface of the skin.
  • Skin aging and inflammation of the skin are closely linked. In inflammation, there is an increase in neutrophil activity that involves a change in the oxidation state of the cell. Free radicals are generated which activate the chemical mediators of inflammation. In skin aging, free radicals are formed from normal metabolism, UV irradiation, and other environmental factors.
  • the use of cerium oxide nanoparticles on the surface of the skin may prevent aging of the skin or reduce damage already inflicted on the skin.
  • This embodiment may be used in makeup or anti-aging lotion. It may be in the form of a cream, lotion, gel, solid stick, powder or any other acceptable composition that is known in the art.
  • the cerium oxide nanoparticles can also be used in protection against forms of radiation, such as IN irradiation. It is known in the art that large cerium oxide molecules, as well as other oxide molecules such as zinc oxide, have the ability to protect a subject's skin from UV irradiation caused by the sun's rays. However, it has not been shown until now that cerium oxide nanoparticles, which enter a cell, have protective characteristics against radiation intracellularly. The data presented here shows that cerium oxide nanoparticles can function to protect against forms of radiation such as UV and gamma radiation. The present invention provides a method for protection against other forms of radiation as well, such as beta and X-ray radiation.
  • the mode of action of the cerium particles of the present invention differs from the mode of action of larger particles in that the larger particles known in the art act to block, reflect, etc. UV light from entering cells, whereas the nanoparticles of the present invention act at a biochemical level to counteract the effects of the UV light within the cells.
  • Another embodiment of the invention is prophylactic radioprotection of a subject.
  • a subject requires radiation treatment for cancer, some of the normal, healthy cells surrounding the cancerous cells will be exposed to the radiation as well.
  • the present invention addresses this problem by providing a method for protecting the normal, healthy cells by exposure to the cerium oxide nanoparticles before radiation treatment.
  • a subject can be exposed to cerium oxide nanoparticles for radioprotection in work environments with high radiation exposure or in military or bioterrorism uses.
  • cerium oxide nanoparticles and compositions comprising cerium oxide nanoparticles are provided.
  • the cerium oxide nanoparticles are size-limited and provided in an amount sufficient to provide one or more doses to a subject in need of, or suspected of being in need of, treatment for a disease or disorder involving free radicals.
  • Compositions may comprise cerium oxide particles of the invention along with one or more other substances, which are typically substances that are biologically tolerable in that they may be exposed to living cells without killing the cells.
  • the other substances are pharmaceutically acceptable substances.
  • pharmaceutically acceptable substance is intended to include solvents, coatings, antibacterial and antifungal agents, and any other ingredient that is biologically tolerable.
  • Such carriers include, but are not limited to, water, saline, dextrose solution, human serum albumin, liposomes, and hydrogels.
  • water, saline, dextrose solution, human serum albumin, liposomes, and hydrogels examples of such carriers.
  • Certain aspects of the invention provide for the use of cerium oxide nanoparticles in the treatment of diseases and disorders associated with free radicals, such as oxygen free radicals.
  • the use is in particular for in vivo therapeutic or prophylactic methods of protecting cells from free radical damage.
  • Certain other aspects of the invention provide for the use of cerium oxide nanoparticles in the preparation of compositions for medical use, such as pharmaceutical or therapeutic compositions. In general, use of the particles is in combining them with other substances to make medicinal compositions.
  • a container containing cerium oxide nanoparticles contains a sufficient amount of size-limited cerium oxide nanoparticles made by a method other than a sol-gel method to provide at least one dose of cerium oxide to a subject suffering from, or at risk of suffering from, a disease or disorder involving free radicals, such as oxygen radicals.
  • the container may contain sufficient cerium oxide nanoparticles and, optionally, one or more other biologically tolerable substance, for one dose to a human or non-human animal subject.
  • the container is provided in a package with one or more other containers and/or with one or more articles of manufacture or devices having use in delivery of substances to subjects (e.g., syringes, needles, antiseptic swabs, sterile saline solution).
  • kits comprising one or more containers are provided.
  • the cerium oxide nanoparticles may be provided in any suitable physical form. Thus, they may be provided as dry particles or as part of a liquid composition.
  • the composition typically will comprise water or an aqueous buffer, such as phosphate buffered saline (PBS) or other salt buffers.
  • PBS phosphate buffered saline
  • the liquid composition be suitable for introduction into a living organism or for contact with a living cell without causing deleterious effects, such as cell toxicity.
  • the nanoparticles may be in a purified state or may be in a composition comprising one or more other component. It is preferred that the other component(s) be non-toxic or, if toxic, present in an amount that, when administered, is not toxic to the cell or subject as a whole.
  • non-toxic components include, but are not limited to, salts (e.g., sodium salts such as sodium phosphate or sodium chloride); sugars (e.g., glucose, sucrose); preservatives; and antibiotics, anti-inflammatories, albumin, lipids, or other drugs.
  • the vehicle of delivery may be in the form of an oral solution, gel, tablet, capsule, powder, suppository, infusible, losenge, cream, salve, inhalant, or injection.
  • the particles or composition comprising the particles will be sterile or will have been sterilized prior to administration to a subject or other use.
  • the particles may be sterilized using any suitable technique known in the art, including, but not limited to, heat sterilization, filtration, and irradiation.
  • the method of the invention further comprises providing sterile or sterilized cerium oxide nanoparticles, or further comprises sterilizing the nanoparticles prior to administering them to a subject.
  • compositions comprising cerium oxide nanoparticles.
  • the compositions can comprise a pharmaceutically suitable carrier, a nutritional supplement, or a dietary supplement. While not being so limited, typically the compositions comprise one or more other substances other than the nanoparticles, where the other substances are biologically tolerable (i.e., non-toxic or present in an amount that is non-toxic). Examples of such substances are well known to those of skill in the art and include, without limitation, sugars, salts, lipids, drugs, excipients, carriers, flavorants, fillers, binders, gums, colorants, water, buffers, detergents, biologically active compounds, and the like.
  • kits comprise cerium oxide nanoparticles in an amount sufficient to treat at least one patient at least one time to reduce or eliminate free radicals that can cause cell, tissue, or organ damage.
  • the nanoparticles of the kit will be supplied in one or more container, each container containing a sufficient amount of nanoparticles for at least one dosing of the patient.
  • the kits can comprise other components, such as some or all of the components necessary to practice a method of the invention.
  • albumin is included, either as a separate component or as part of a composition comprising the nanoparticles.
  • the albumin is provided to lessen the amount or use of disruption of the nanoparticles, for example by sonication at 5-20 Hz for 2 minutes, that can sometimes be needed to provide certain formulations for delivery.
  • the kits may contain a syringe for administering a dose of the nanoparticles.
  • the kits may also comprise filters for sterilization of the particles prior to delivery; however, it is preferred that the particles be sterilized prior to packaging in the kits, or the entire kit be sterilized after all components are packaged. It may likewise contain sterile water or buffer for rehydration or reconstitution of dry nanoparticles, prior to administration of the particles to a patient.
  • kits according to the invention may comprise liposomes, particularly liposomes loaded with the nanoparticles.
  • a single 10 nM dose of cerium oxide nanoparticles extended the life span of cultured rat brain cells (neurons, astrocytes, microglia) from 28 to 182 days (6 months).
  • the nanoparticles were in a non-agglomerated form.
  • stock solutions of about 10% by weight were sonicated in ultra-high purity water (16 megaohms) or in normal saline prepared with ultra high purity water.
  • Stocks were sonicated with a probe sonicator for 3 minutes. Dilutions were made, beginning with 10 mM, down to 100 nM or lower. No phosphate or other ionic buffers were used because these were found to increase agglomeration.
  • FIG. 1 depicts the results of experiments to determine the effect of nanoparticles on the maximum lifespan of organotypic brain cells in culture.
  • the mixed brain cell cultures from rat cerebral cortex were treated with 10 nM cerium oxide nanoparticles on day 10 in vitro. Controls received vehicle alone (normal saline). The figure shows that the nanoparticles has a dramatic effect on cell lifespan.
  • DIV Days In Vitro
  • FIG. 2 depicts the results of experiments to determine the effect of nanoparticles on the lifespan of Drosophila melanogaster .
  • the results show that the lifespan of the flies is significantly increased.
  • Drosophila melanogaster (Oregon R strain) were fed from enclosure with standard mix fly food with or without cerium oxide nanoparticles at the indicated concentrations. Note that not only is the maximum lifespan increased, but the time to 50% population death in increased in nanoparticle-treated vs. controls (dotted lines). Flies were fed food containing the indicated concentration of cerium oxide nanoparticles, from enclosure throughout the lifetime.
  • cerium oxide nanoparticles were prepared as described above (sonication methods) and added to the fly food (Jazz Mix) during preparation (i.e., while the fly food remained in liquid form). Food was sonicated 5 min after addition of particles, to ensure non-agglomerated suspension of nanoparticles in the food medium. Flies were growth under standard conditions, in vials containing 5 ml food medium and 20 flies per vial. Dead flies were counted every 1-2 days.
  • cerium oxide nanoparticles promoted cell longevity by acting as free radical scavengers.
  • cerium oxide nanoparticles were capable of enhancing longevity. Further, cerium oxide nanoparticles provided superior protection to free radical mediated injury, as compared to single and multiple doses of traditional free radical scavengers.
  • cerium oxide nanoparticles act via a free radical scavenging mechanism
  • excitation scans reveal a peak excitation of 451 for cerium oxide nanoparticles in the reduced (+4) valence state.
  • the excitation maxima shifts to 356 nm, suggesting a change in cerium to the +3 valence state.
  • the excitation spectra returns to the normal resting state, with a peak maxima of 451 excitation, suggesting regeneration of the original cerium oxide lattice structure.
  • FIG. 3 depicts the excitation spectra for intracellular cerium oxide nanoparticles, and shows that the spectra is altered during a free radical scavenging event.
  • astrocytes were treated with 10 nM cerium oxide nanoparticles on day 10 in vitro, and examined fluorimetrically on day 18.
  • Cell cultures were washed, placed in phosphate buffered saline, and subjected to excitation spectra scan as shown. Emission was measured above 510 nm. Excitation scans were collected every 0.01 msec using a high speed DeltaRam Scanner, during the addition of 100 uM H 2 O 2 as a free radical-generating agent.
  • Controls (untreated) cells revealed no fluorescence emission in the range and magnitude shown.
  • the shift in excitation spectra of cerium indicates an electron shuffling event in the oxide lattice or cerium atom, as shown in FIG. 3 .
  • These results demonstrate that a similar shift in excitation spectra occurs in cells containing cerium oxide nanoparticles, which occurs during a reaction with a free radical, such as that generated by H 2 O 2 .
  • the return to 456 nm excitation maxima suggests that the cerium oxide nanoparticle can regenerate its free radical scavenging capacity while in the cell.
  • cerium oxide nanoparticles of size less than 20 nm readily enter cultured cells and cells of living organisms. Further, doses as high as 100-fold of that which extend cell culture lifespan exhibited no overt toxicity in Drosophila . A single tail vein injection of 0.3-3 mM in the mouse produced no overt organ or behavioral abnormalities. Cerium oxide nanoparticles were found to accumulate preferentially in brain, heart, and lung with little excretion over a 6 month time period. At the 0.3 mM dose, tissue cerium levels approximately doubled (as compared to background), but remained in the parts per billion range.
  • FIG. 4 depicts the results of tissue cerium measurements of mice treated with nanoparticles. More specifically, Balb/c mice were administered 5-10 ul tail vein injections each containing 300 nmoles cerium oxide nanoparticles. After 3 months, mice were euthanized and organs were harvested. Tissue cerium was measured by inductively coupled plasma mass spectrometry. It is interesting to note that the highest increases in tissue cerium concentration occurred in brain, heart, and lung, the most oxidative organs in the body.
  • brain cell injury in response to trauma may be related, in part, to generation of free radicals induced by injury.
  • Brain cell cultures treated with cerium oxide nanoparticles on day 10 in vitro showed a 60-70% reduction in cell injury when trauma was administered on days 15-18 in vitro.
  • delivery of cerium oxide nanoparticles up to 3 hrs post-injury reduced neuronal death by 40-50%, depending on the degree of injury.
  • cerium oxide nanoparticles represent a treatment for trauma and other forms of neurodegeneration associated with free radical injury.
  • neuronal dysfunction In brain trauma, neuronal dysfunction often manifests, causing persistent neurological deficits. Here, we demonstrate this correlates to human head injury with an in vitro model. We found that pre- or post-injury delivery of nanoparticles significantly reduced neuronal dysfunction, as measured by neurotransmitter-stimulated calcium signaling, in both astrocytes and neurons.
  • FIG. 5 shows the effect of nanoparticles on brain cells subjected to trauma.
  • Mixed organotypic brain cell cultures were subjected to in vitro trauma as previously described (Zhang, Rzigalinski, et al. Science 274: 1921-1923, 1997).
  • Cerium oxide nanoparticles (10 nM) were delivered to the cultures either on day 10 in vitro or 3 hours post injury and neuronal death was assessed by propidium iodide staining at 24 hrs post injury. The positive effects on cells is evident.
  • FIG. 6 further shows the effect of nanoparticles on brain cells subjected to trauma.
  • Mixed organotypic brain cells were subjected to in vitro trauma as described above.
  • Cerium oxide (10 nM) nanoparticles were delivered 3 hrs post injury and neuronal intracellular free calcium ([Ca 2+ ] i ) signaling was determined at 24 hrs post injury using Fura-2 microspectrophotometry.
  • Uninjured neurons (solid black line) showed regular intracellular free calcium oscillations, indicative of robust inter-neuronal signaling.
  • Glutamate induced a rise in [Ca 2+ ] i to 262 nM, followed by a return to basal.
  • cerium oxide nanoparticles to be potent inhibitors of inflammation and inflammatory cell damage. Our studies indicate that cerium oxide nanoparticles reduce the inflammatory response in brain microglia (MG), reduce neuronal death induced by activated, inflammatory brain MG, as well as reduce the release of interleukin 1- ⁇ and inflammatory mediators of the arachidonic acid cascade in brain MG.
  • MG brain microglia
  • cerium oxide nanoparticles reduce the inflammatory activation state of human neutrophil and macrophage like cells lines, HL-60 and U937 and reduce the inflammatory response initiated by histamine, bacterial lipopolysaccharide (LPS), and fMLP (f-met-leu-phe, chemotactic peptide) in human neutrophil and macrophage-like cell lines (HL-60 & U937). Therefore, cerium oxide nanoparticles represent a novel treatment for inflammatory and immune disorders.
  • LPS bacterial lipopolysaccharide
  • fMLP f-met-leu-phe, chemotactic peptide
  • FIG. 7 shows that cerium oxide nanoparticles reduce the inflammatory response initiated by lipopolysaccharide (LPS).
  • LPS lipopolysaccharide
  • Nitric Oxide Nitric Oxide
  • MG were treated once with 10 nM CeO 2 —NP for 24 hrs, to allow uptake of nanoparticles. After washing and changing the media, MG were treated with 100 ng/ml LPS to induce the inflammatory response. Morphology and release of NO were examined. MG exposed to 100 ng/ml LPS for 24 hours exhibited release of NO of 16.1 mM. When treated with 10 nM CeO 2 —NP for 24 hours prior to exposure, NO release decreased by 62.0%, demonstrating that CeO 2 —NP does decrease release of inflammatory mediators that may enhance neuronal death.
  • NO Nitric Oxide
  • FIG. 8A resting MG have compact cell bodies with long, branched processes.
  • FIG. 8B MG were stimulated with LPS. Note the dramatic morphological changes as compared to the resting state ( 8 A). LPS-induced morphological changes are blocked by CeO 2 —NP as shown in 8 C.
  • Cerium oxide nanoparticles reduced brain cell death associated with 1, 3, and 5 Gray by 78, 62, and 48%, respectively.
  • a single 10 nM dose of nanoparticles was administered on day 10 in vitro, with irradiation of cultures on day 12-15. Further, a reduction in injury was observed even when particles were administered up to 3 hrs post irradiation.
  • FIGS. 9 and 10 show the effect of pretreatment with cerium oxide nanoparticles on exposure to radiation.
  • Mixed organotypic rat brain cells were obtained from neonatal rat pups and cultures as previously described (Zhang et al., Science, 274, 1921-1923, 1996.). Cultures were treated +10 nM CeO 2 —NP on day 10 in vitro, by delivery to the tissue culture medium for 24 hrs, followed by regular medium replacements. After 14-16 DIV, free radical damage was assessed by exposure to ultraviolet light for increments of 5 minutes or 15 minutes, followed by measurement of cell death with Propidium Iodide (PrI). For gamma-irradiation studies, cells were exposed to 1.5 or 5 Gray radiation for 1 minute. Additionally, aged cultures (68 DIV) treated with CeO 2 —NP were also exposed to UV and gamma-irradiation, to determine whether the protective effects of CeO 2 —NP were maintained in aged cultures.
  • PrI Propidium Iodide
  • FIGS. 11 and 12 show that cerium oxide nanoparticles provide greater protection against free radical mediated injury as compared to single or multiple doses of Vitamin E, n-Acetyl Cysteine, or Melatonin.
  • cells were cultured in 6-well plates. Three wells were used as controls while the other three were treated with one of the following agents at 10-DIV: 10 nM Cerium Oxide nanoparticles, 100 mM Vitamin E, 1 mM n-Acetyl Cysteine, or 1 mM Melatonin. Drugs were delivered directly into the tissue culture media and remained in the media for 24 his, followed by media replacement. Nanoparticles were only delivered once, at 10 DIV. Other agents were delivered in single or multiple doses as indicated. After 14-16 DIV, free radical damage was assessed by exposure to ultraviolet light for increments of 5 minutes or 15 minutes, followed by measurement of cell death with Propidium Iodide (PrI).
  • PrI Propidium Iodide
  • cerium oxide nanoparticles or other free radical scavengers were delivered to the tissue culture medium on DIV 10. Medium was replaced 48 hrs later, followed by regular medium changes every 2-3 days. UV exposure was performed on DIV 14. Cerium Oxide nanoparticles reduced UV-light induced cell death 24 hr after a 5 or 15 min. exposure, by 58%. MEL reduced cell death associated with short term (5 min) UV exposure to a similar extent, but was less effective after a long term (15 min) exposure. Vitamin E afforded a modest degree of protection.
  • FIGS. 13 and 14 show that both male and female Drosophila life spans are increased when cerium oxide nanoparticles are given to the flies. These longevity studies were performed by adding 10 nM CeO 2 —NP directly to the fly food. To determine the effect of CeO 2 —NP on survival after free radical challenge, male and female flies were cultured continuously from the day of enclosure on fly food containing 10 nM CeO2-NP. On day 35, flies were exposed to filter paper saturated with 20 mM paraquat in 5% sucrose solution for 24 hrs. Paraquat is a redox cycling pesticide known to induce fly death via free radical production. Dead flies were counted at regular intervals.
  • FIG. 15 shows the amount of neuron specific enolase (NSE) in tissue culture. As neurons die off in a culture, they release a characteristic enzyme, NSE. This experiment shows the amount of NSE in the tissue culture medium, as a percentage of the total left in the cultures. NSE release increases dramatically in the medium over days 20-26, as the neurons die and lyse. At day 30, all the neurons are dead. In the cerium oxide treated group (triangles), the NSE in the medium does not rise, but stays at basal levels, denoting that all the neurons are still alive.
  • NSE neuron specific enolase
  • FIG. 16 shows the percentage of tissue cultures surviving with robust neurons and astrocytes. This experiment summarizes data for over 75 control and cerium oxide-treated cultures. Each culture was treated with a single dose of 10 nM cerium oxide nanoparticles on day 10 in vitro. This experiment demonstrates that cerium oxide nanoparticles increase the longevity of the cultures.
  • FIGS. 17 through 20 show that 10 nM cerium oxide nanoparticles significantly extend the average and maximum lifespan of male and female Drosophila when the fruit flies are introduced to paraquat, an oxidative stress inducer.
  • cerium oxide nanoparticles act as free radical scavengers in Drosophila melanogaster .
  • paraquat methyl viologen
  • paraquat is routinely used to test effects of various biochemical agents on reduction of oxidative stress, via examining survival after paraquat challenge.
  • FIGS. 21 and 22 show that cerium oxide nanoparticles provide enhanced protection against traumatic injury as compared to a single dose of other antioxidants when given either pre-trauma ( FIG. 21 ) or post trauma ( FIG. 22 ).
  • traumatic injury of mixed brain cell cultures produces cell death, in part, via generation of free radicals (Hoffman et al., Lamb, et al. J. Neurochem; 68, 1904-1910, 1997).
  • Mixed brain cell cultures were injured at mild (5.5 mm), moderate (6.5 mm), and severe (7.5 mm) levels, and cell death was assessed with PrI, 24 hrs post injury.
  • FIGS. 23 to 26 show that cerium oxide nanoparticles decrease the release of NO from brain microglia.
  • Pure cultures of astrocytes were injured using a well-characterized model for in vitro trauma. We have previously shown that exposure to medium conditioned by traumatically injured astrocytes induces microglial activation. MG so activated induce neuronal death. In these experiments microglia were activated by a 24 hour exposure to medium conditioned by mild, moderate, or severely injured astrocytes. Controls consisted of microglia exposed to medium conditioned by uninjured astrocytes. In these experiments, LPS was utilized as positive control.
  • LPS acting as an endotoxin, binds to receptors on microglia and triggers the secretion of pro-inflammatory cytokines and promotes the release of NO.
  • Control or nano-treated microglia were exposed to 100 ng/ml LPS for 24 hours followed by measurement of NO released into the medium, as represented in FIG. 5 .
  • NO was measured using kits provided by Oxis International and Calbiochem, via the Griess reaction. Absorbance was read in a BioTek ELx800 automated plate reader at 540 nm.
  • MG exposed to 100 ng/ml LPS for 24 hours exhibited release of NO of 16.1 mM.
  • NO release decreased by 62.0%, demonstrating that Cerium Oxide nanoparticles decrease release of inflammatory mediators that may enhance neuronal death.
  • resting MG have compact cell bodies with long, branched processes.
  • MG activated by exposure to medium conditioned by severely injured astrocytes become more amoeboid in shape, with refracted, short processes and highly granulated and vacuolated cytoplasms.
  • Pretreatment with Cerium Oxide nanoparticles prevent some of the morphological changes observed in MG activation.
  • MG were also stimulated with LPS. Note the dramatic morphological changes as compared to the resting state. LPS-induced morphological changes are blocked by Cerium Oxide nanoparticles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
US11/993,260 2005-06-27 2006-06-27 Anti-Inflammatory, Radioprotective, and Longevity Enhancing Capabilities of Cerium Oxide Nanoparticles Abandoned US20100166821A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/993,260 US20100166821A1 (en) 2005-06-27 2006-06-27 Anti-Inflammatory, Radioprotective, and Longevity Enhancing Capabilities of Cerium Oxide Nanoparticles

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69393005P 2005-06-27 2005-06-27
US11/993,260 US20100166821A1 (en) 2005-06-27 2006-06-27 Anti-Inflammatory, Radioprotective, and Longevity Enhancing Capabilities of Cerium Oxide Nanoparticles
PCT/US2006/024963 WO2007002662A2 (en) 2005-06-27 2006-06-27 Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/024963 A-371-Of-International WO2007002662A2 (en) 2005-06-27 2006-06-27 Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/252,905 Continuation-In-Part US10857178B2 (en) 2005-06-27 2008-10-16 Cerium oxide nanoparticles for treatment and prevention of Alzheimer's disease, Parkinson's disease, and disorders associated with free radical production and/or mitochondrial dysfunction
US13/539,564 Continuation US8747907B2 (en) 2005-06-27 2012-07-02 Anti-inflammatory, radioprotective, and longevity enhancing capabilities of ceriumoxide nanoparticles

Publications (1)

Publication Number Publication Date
US20100166821A1 true US20100166821A1 (en) 2010-07-01

Family

ID=37595977

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/993,260 Abandoned US20100166821A1 (en) 2005-06-27 2006-06-27 Anti-Inflammatory, Radioprotective, and Longevity Enhancing Capabilities of Cerium Oxide Nanoparticles
US13/539,564 Active US8747907B2 (en) 2005-06-27 2012-07-02 Anti-inflammatory, radioprotective, and longevity enhancing capabilities of ceriumoxide nanoparticles

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/539,564 Active US8747907B2 (en) 2005-06-27 2012-07-02 Anti-inflammatory, radioprotective, and longevity enhancing capabilities of ceriumoxide nanoparticles

Country Status (6)

Country Link
US (2) US20100166821A1 (enExample)
EP (1) EP1904072A4 (enExample)
JP (1) JP2008546842A (enExample)
AU (1) AU2006261764A1 (enExample)
CA (1) CA2613086A1 (enExample)
WO (1) WO2007002662A2 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092671A1 (en) * 2005-06-27 2009-04-09 Rzigalinski Beverly A Cerium Oxide Nanoparticles for Treatment and Prevention of Alzheimer's Disease, Parkinson's Disease, and Disorders Associated with Free Radical Production and/or Mitochondrial Dysfunction
US20100239687A1 (en) * 2007-05-11 2010-09-23 Taewung Els, Inc. Uses of rare earth elements for slimming
US8333993B1 (en) * 2006-12-29 2012-12-18 University Of Central Florida Research Foundation, Inc. Synthesis of polymer coated ceria nanoparticles for biomedical applications
WO2013151698A1 (en) * 2012-04-04 2013-10-10 Duke University Methods for using cerium oxide nanoparticles to mitigate or protect against radiation injury
WO2014008503A1 (en) * 2012-07-06 2014-01-09 University Of Central Florida Research Foundation, Inc. Methods of using ceo2 and tio2 nanoparticles in modulation of the immune system
EP2633315A4 (en) * 2010-10-25 2014-03-26 Entomopharm Aps EX VIVO-BASED INSECT MODEL FOR TESTING HEMATO-ENCEPHALIC BARRIER PENETRATION AND METHOD FOR EXPOSING INSECT BRAIN TO NANOPARTICLES
US9119391B1 (en) * 2007-07-16 2015-09-01 University Of Central Florida Research Foundation, Inc. Polymer coated ceria nanoparticles for selective cytoprotection
US20160015741A1 (en) * 2013-03-01 2016-01-21 University Of Central Florida Research Foundation, Inc. Cerium Oxide Nanoparticles Accelerate the Decay of Peroxynitrite (ONOO-)
US9649337B2 (en) 2005-06-27 2017-05-16 Edward Via Virginia College Of Osteopathic Medicine Cerium oxide nanoparticles for the treatment and prevention of stroke and cardiovascular disease
US9669055B1 (en) * 2014-04-11 2017-06-06 Marshall University Research Corporation Methods for treating sepsis
CN112516294A (zh) * 2020-12-22 2021-03-19 浙江大学 一种氧化铈纳米稳定剂在制备预防过敏性疾病药物中的应用及预防过敏性疾病的药物组合物
US11116792B1 (en) 2010-12-22 2021-09-14 Biocurity Holdings, Inc. Cerium oxide nanoparticle formulation for use in skin radioprotection and associated methods
CN116942695A (zh) * 2022-04-20 2023-10-27 中国科学院深圳先进技术研究院 二氧化铈作为炎症小体抑制剂在疾病治疗中的应用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959949B2 (en) 2006-04-27 2011-06-14 University Of Central Florida Research Foundation, Inc. Functionalized nanoceria composition for ophthalmic treatment
WO2008018932A2 (en) 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
US20080166412A1 (en) 2007-01-02 2008-07-10 Kiminobu Sugaya Methods and materials for stimulating proliferation of stem cell
EP2288258A4 (en) * 2008-04-25 2012-10-31 Univ Oklahoma INHIBITION OF NEOVASCULARIZATION BY CERIUM OXIDE NANOPARTICLES
US8916199B1 (en) 2008-04-25 2014-12-23 University of Central Florida Research Foundation, Ind. Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide
US9127202B1 (en) 2008-07-18 2015-09-08 University Of Central Florida Research Foundation, Inc. Biocompatible nano rare earth oxide upconverters for imaging and therapeutics
US8883519B1 (en) 2009-03-17 2014-11-11 University Of Central Florida Research Foundation, Inc. Oxidase activity of polymeric coated cerium oxide nanoparticles
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
US8795731B1 (en) 2009-10-12 2014-08-05 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation
US20160074434A1 (en) * 2010-07-22 2016-03-17 University Of Central Florida Research Foundation, Inc. Application Device for Inducing Cytotoxicity to Tumor Cells Via Coated Cerium Oxide Nanoparticles
WO2012036786A1 (en) 2010-09-17 2012-03-22 University Of L'aquila Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease
US8951539B1 (en) 2011-06-07 2015-02-10 University Of Central Florida Research Foundation, Inc. Methods of promoting angiogenesis using cerium oxide nanoparticles
US9161950B2 (en) 2011-09-21 2015-10-20 University Of Central Florida Foundation, Inc. Neuronal protection by cerium oxide nanoparticles
WO2013158744A2 (en) 2012-04-17 2013-10-24 Cerion Enterprises, Llc Nanoparticles of cerium and amino acids
US9446070B2 (en) 2012-06-13 2016-09-20 Cerion, Llc Nanoceria with citric acid additive
JP6174692B2 (ja) 2012-06-13 2017-08-02 セリオン エンタープライジズ リミテッド ライアビリティ カンパニー 酸化ストレスの処置のためのナノセリア
US9463437B2 (en) 2013-02-14 2016-10-11 University Of Central Florida Research Foundation, Inc. Methods for scavenging nitric oxide using cerium oxide nanoparticles
US9549950B2 (en) 2013-04-25 2017-01-24 Cerion, Llc Chelated nanoceria for the treatment of oxidative stress
US9623110B2 (en) 2013-08-09 2017-04-18 Cerion, Llc Nanoparticles of a metal and a nucleobase
WO2015058037A1 (en) 2013-10-17 2015-04-23 Cerion, Llc Malic acid stabilized nanoceria particles
CN103983777A (zh) * 2014-05-07 2014-08-13 大连理工大学 一种基于纳米二氧化铈仿生氧化酶的微囊藻毒素比色检测方法
AU2015289504B2 (en) * 2014-07-17 2020-12-17 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
JP2018508568A (ja) 2015-01-20 2018-03-29 セリオン，リミティド ライアビリティ カンパニー カタラーゼ様活性を有するｅｄｄｓでキレート化されたナノセリア
JP2016204368A (ja) * 2015-04-14 2016-12-08 株式会社Ａｐｐｌａｕｓｅ 酸化セリウム微粒子を含有する組成物
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
US11833172B2 (en) 2015-11-25 2023-12-05 The Regents Of The University Of Colorado Use of microRNA-146A and nanoceria conjugate to improve wound healing and promote tissue regeneration
KR101696903B1 (ko) 2016-04-20 2017-01-17 서울대학교병원 세리아 나노복합체를 포함하는 비외상성 두개내 출혈 치료용 약학적 조성물
CN107789627B (zh) * 2017-09-26 2021-05-07 西北农林科技大学 可降解聚多巴胺包封的靶向双刺激响应性多功能二氧化铈纳米载药体系
KR102102535B1 (ko) * 2018-07-26 2020-04-21 서울대학교산학협력단 방사선 보호 나노입자
EP3867407A4 (en) * 2018-07-26 2022-09-14 Edward Via College of Osteopathic Medicine BLOOD PRESERVATION COMPOSITIONS, DEVICES, AND USES THEREOF
JP7328480B2 (ja) * 2018-09-14 2023-08-17 株式会社applause Pharma チロシン－チロシナーゼ反応阻害剤
WO2020069292A1 (en) * 2018-09-28 2020-04-02 The Regents Of The University Of Colorado, A Body Corporate Methods for preventing and treating pulmonary inflammation and fibrosis
US12480009B2 (en) 2021-07-30 2025-11-25 Xheme Inc. Nanoporous cerium oxide nanoparticle macro-structure
WO2023060246A1 (en) * 2021-10-08 2023-04-13 Xheme Inc. Blood preservation compositions, devices and uses thereof utilizing: a. zirconium dioxide nanoparticles or nanoporous zirconium dioxide nanoparticle macrostructures; and b. nanoporous cerium oxide nanoparticle macrostructures
CN116270729A (zh) * 2022-11-09 2023-06-23 西安交通大学医学院第一附属医院 多孔纳米棒状氧化铈在制备治疗特应性皮炎的药物中的应用
AU2024285952A1 (en) * 2023-06-09 2025-12-04 Xheme Inc. Bioreactors providing cerium oxide and zirconium dioxide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030231992A1 (en) * 2002-06-17 2003-12-18 Sarkas Harry W. Process for preparing nanostructured materials of controlled surface chemistry
US20050066571A1 (en) * 2001-11-06 2005-03-31 Gareth Wakefield Cerium oxide nanoparticles
US20060246152A1 (en) * 2005-04-29 2006-11-02 Mcginnis James F Inhibition of reactive oxygen species and protection of mammalian cells
US7534453B1 (en) * 2002-09-05 2009-05-19 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticles and use in enhancing cell survivability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG38903A1 (en) * 1995-03-16 1997-04-17 Gen Electric Acrylic coatings containing inorganic UV screen
JP2746861B2 (ja) * 1995-11-20 1998-05-06 三井金属鉱業株式会社 酸化セリウム超微粒子の製造方法
US6413489B1 (en) * 1997-04-15 2002-07-02 Massachusetts Institute Of Technology Synthesis of nanometer-sized particles by reverse micelle mediated techniques
JP4054869B2 (ja) * 2002-12-25 2008-03-05 独立行政法人産業技術総合研究所 抵抗型酸素センサの酸素分圧検出部分の製造方法
DE10337199A1 (de) * 2003-08-13 2005-03-10 Degussa Ceroxidpulver

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050066571A1 (en) * 2001-11-06 2005-03-31 Gareth Wakefield Cerium oxide nanoparticles
US20030231992A1 (en) * 2002-06-17 2003-12-18 Sarkas Harry W. Process for preparing nanostructured materials of controlled surface chemistry
US7534453B1 (en) * 2002-09-05 2009-05-19 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticles and use in enhancing cell survivability
US20060246152A1 (en) * 2005-04-29 2006-11-02 Mcginnis James F Inhibition of reactive oxygen species and protection of mammalian cells
US7347987B2 (en) * 2005-04-29 2008-03-25 University Of Central Florida Research Foundation, Inc. Inhibition of reactive oxygen species and protection of mammalian cells

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10857178B2 (en) * 2005-06-27 2020-12-08 Edward Via Virginia College Of Osteopathic Medicine Cerium oxide nanoparticles for treatment and prevention of Alzheimer's disease, Parkinson's disease, and disorders associated with free radical production and/or mitochondrial dysfunction
US20090092671A1 (en) * 2005-06-27 2009-04-09 Rzigalinski Beverly A Cerium Oxide Nanoparticles for Treatment and Prevention of Alzheimer's Disease, Parkinson's Disease, and Disorders Associated with Free Radical Production and/or Mitochondrial Dysfunction
US9649337B2 (en) 2005-06-27 2017-05-16 Edward Via Virginia College Of Osteopathic Medicine Cerium oxide nanoparticles for the treatment and prevention of stroke and cardiovascular disease
US8333993B1 (en) * 2006-12-29 2012-12-18 University Of Central Florida Research Foundation, Inc. Synthesis of polymer coated ceria nanoparticles for biomedical applications
US20100239687A1 (en) * 2007-05-11 2010-09-23 Taewung Els, Inc. Uses of rare earth elements for slimming
US9119391B1 (en) * 2007-07-16 2015-09-01 University Of Central Florida Research Foundation, Inc. Polymer coated ceria nanoparticles for selective cytoprotection
EP2633315A4 (en) * 2010-10-25 2014-03-26 Entomopharm Aps EX VIVO-BASED INSECT MODEL FOR TESTING HEMATO-ENCEPHALIC BARRIER PENETRATION AND METHOD FOR EXPOSING INSECT BRAIN TO NANOPARTICLES
US11116792B1 (en) 2010-12-22 2021-09-14 Biocurity Holdings, Inc. Cerium oxide nanoparticle formulation for use in skin radioprotection and associated methods
WO2013151698A1 (en) * 2012-04-04 2013-10-10 Duke University Methods for using cerium oxide nanoparticles to mitigate or protect against radiation injury
US20150056283A1 (en) * 2012-04-04 2015-02-26 University Of Central Florida Research Foundation, Inc. Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury
US9415065B2 (en) * 2012-04-04 2016-08-16 University Of Central Florida Research Foundation, Inc. Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury
WO2014008503A1 (en) * 2012-07-06 2014-01-09 University Of Central Florida Research Foundation, Inc. Methods of using ceo2 and tio2 nanoparticles in modulation of the immune system
US20160015741A1 (en) * 2013-03-01 2016-01-21 University Of Central Florida Research Foundation, Inc. Cerium Oxide Nanoparticles Accelerate the Decay of Peroxynitrite (ONOO-)
US9669055B1 (en) * 2014-04-11 2017-06-06 Marshall University Research Corporation Methods for treating sepsis
CN112516294A (zh) * 2020-12-22 2021-03-19 浙江大学 一种氧化铈纳米稳定剂在制备预防过敏性疾病药物中的应用及预防过敏性疾病的药物组合物
CN116942695A (zh) * 2022-04-20 2023-10-27 中国科学院深圳先进技术研究院 二氧化铈作为炎症小体抑制剂在疾病治疗中的应用

Also Published As

Publication number Publication date
US20130004584A1 (en) 2013-01-03
AU2006261764A1 (en) 2007-01-04
CA2613086A1 (en) 2007-01-04
WO2007002662A3 (en) 2007-11-22
JP2008546842A (ja) 2008-12-25
EP1904072A4 (en) 2009-06-17
WO2007002662A2 (en) 2007-01-04
US8747907B2 (en) 2014-06-10
EP1904072A2 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
US8747907B2 (en) Anti-inflammatory, radioprotective, and longevity enhancing capabilities of ceriumoxide nanoparticles
CN104220057B (zh) 药物组合物和方法
KR102184722B1 (ko) 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도
JP6295249B2 (ja) レチノイドアゴニストを用いた好中球減少症の治療方法
JP6099214B2 (ja) 電離放射線誘発の損傷から哺乳類細胞を保護する医薬組成物
US9649337B2 (en) Cerium oxide nanoparticles for the treatment and prevention of stroke and cardiovascular disease
JPH10502371A (ja) リンホトキシンを用いる癌処置法
JPH10511974A (ja) リソチーム二量体の新しい応用
Rani et al. Metallic Nanoparticles Applications in Medicine
Verma et al. Metal nanoparticle based antibacterial nanocomposites for skin infections
CN117883409A (zh) 一种植物来源外泌体包裹的载药钙基纳米发生器及其制备方法和抗肿瘤应用
Molento et al. The breakthrough of nanotechnology to veterinary parasitology research
US20190234933A1 (en) Compositions and assays
US20240156875A1 (en) Equine-specific therapeutic compositions and methods of use
US20240415937A1 (en) Theophylline-loaded collagen nanoparticles
CN118021939A (zh) Bmp4蛋白或其衍生物在制备药物中的用途
CN109331187A (zh) 间充质干细胞制剂致敏性的评价方法和应用
RU2437675C1 (ru) Гемостимулирующее средство
Zhang et al. Black Phosphorus Quantum Dots Effectively and Safely Treat Glaucoma as a Promising Anti-Ferroptosis Nano-drug
CN120324578A (zh) 一种trem-1抑制肽纳米颗粒及其制备方法和应用
CN118021805A (zh) 一种新型的辐射损伤保护剂及其应用
DE19643093C2 (de) Verwendung von FasL oder mit FasL transfizierten CD4·+·/FasL·-·/TH1-Zellinien oder von FasL in Kombination mit einem oder mehreren Cytokin(en) zur Bekämpfung von TH1/TH2-Krankheiten
CN118021840A (zh) 治疗神经退行性疾病的纳米酶及用途
Nagler et al. Redox metal chelation ameliorates radiation-induced bone marrow toxicity in a mouse model
JP2008534624A (ja) インドロキノンによる腫瘍の放射線増感

Legal Events

Date Code Title Description
AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:VIRGINIA COLLEGE OF OSTEOPATHIC MEDICINE;REEL/FRAME:027931/0818

Effective date: 20120305

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION